Leukapheresis
Return to Library
|
Free Leukapheresis Articles |
|
|
|
|
Research reports from Karolinska Institute Cancer Center provide new insights into vaccines
2009 JUN 1 - (NewsRx.com) -- Research findings, 'Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production,' are discussed in a new report. According to recent research from Stockholm, Sweden, "We previously demonstrated that dendritic cells (DC) that have endocytosed apoptotic bodies of autologous leukemic cells (Apo-DC) can boost antileukemic T-cell responses. In this study, we report a description of the production procedure and product specification of the Apo-DC vaccine preparations for clinical use." "Enriched populations of CD14+ monocytic precursors and CD19+ leukaemic cells were obtained using CliniMACS technology from a single leukapheresis product. Apoptotic bodies were obtained by irradiating (5 Gy) CD19+ selected B cells. DC were generated ex vivo by culturing monocytes with granulocyte macrophage colony-stimulating factor and interleukin-4. Following coculture with apoptotic bodies, DCs were matured with tumor necrosis factor-alpha. The mean percentage of CD14+ cells in the peripheral blood as well as in the leukapheresis product of the patients (n=10) was approximately 2% (range, 0.8-3.3). Immunomagnetic selection using the CD14 reagent yielded a CD14+ population that was 91 ±2.2% (mean ±SEM) pure. Immunomagnetic selection of CD19 expressing cells yielded a population that was 100 ±0.03% pure. Cell viability immediately after selection was 97% and 98% after 7 days of culture. The Apo-DC cellular vaccine product showed a mature phenotype, with a high rate of endocytosis (84%) of apoptotic leukemic B-cells," wrote L. Adamson and colleagues, Karolinska Institute Cancer Center. The researchers concluded: "Despite significant variability in the circulating monocyte frequency of the chronic lymphocytic leukaemia patients, our method permitted the production of a DC vaccine with high reproducibility and conforming with recommended quality standards." Adamson and colleagues published their study in Scandinavian Journal of Immunology (Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production. Scandinavian Journal of Immunology, 2009;69(6):529-36). For additional information, contact L. Adamson, Immune and Gene Therapy Laboratory, Dept. of Oncology & Pathology, Cancer Centre Karolinska, Stockholm, Sweden. Publisher contact information for the Scandinavian Journal of Immunology is: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA. Keywords: Sweden, Stockholm, Biotechnology, Blood Transfusion, Cancer Vaccines, Hematology, Immunology, Leukapheresis Products, Medical Device, Necrosis, Oncology, Transfusion Medicine. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
